Key statistics
On Friday, Transgene SA (TGNA:FRA) closed at 0.786, 42.91% above the 52 week low of 0.55 set on May 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.786 |
|---|---|
| High | 0.786 |
| Low | 0.786 |
| Bid | 0.784 |
| Offer | 0.864 |
| Previous close | 0.822 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 274.19m |
| Free float | 177.19m |
| P/E (TTM) | -- |
| Market cap | 230.32m EUR |
| EPS (TTM) | -0.1456 EUR |
Data delayed at least 15 minutes, as of Feb 06 2026 07:04 GMT.
More ▼
Announcements
- Transgene présente son calendrier de communication financière pour 2026
- Transgene Announces Financial Calendar for 2026
- Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
- Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer
- Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2025
- Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025
- Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
- Transgene publie les données de Phase I confirmant le potentiel de TG4050 à réduire le risque de récidive des cancers de la tête et du cou
- Transgene to Participate in Upcoming Investor Meetings
- Transgene annonce ses prochaines rencontres avec les investisseurs
More ▼
